RESUMO

The Polo Argentino (PA) horse is a recognized breed, developed originally by mixing crossbred and Thoroughbred (TB) horses to play polo. Early PA selection is difficult due to unreliable performance estimations. This study investigated the usefulness of genomic markers previously linked to morphological and functional traits as a tool for the early selection of PA. To this, we genotyped 520 PA and 30 TB horses using the Equine GGPArray (Illumina, n = 71,778 SNPs). Analyses included a genetic characterization of six genetic markers associated with behavioral (DRD4), muscular development (MSTN), and body size (LCORL, HMGA6, ZFAT, and LASP1) genes. Genetic differences in the DRD4, MSTN, and LCORL SNP were found between the two breeds, in the last two FST index between breeds was 0.13 and 0.6, respectively (p < 0.01). In DRD4, G allele was the more prevalent in PA (0.56 vs 0.45 in TB, p < 0.05), but no differences were observed between the genotypes associated with phenotypes. In MSTN, heterozygous genotypes were the most common in PA (48 %), with a significant decrease in AA (Hardy-Weinberg p < 0.05), suggesting a negative selection against it in polo horses. In body size, HMGA2 was monomorphic in all horses, while ZFAT and LASP1 SNP showed higher variability. Interestingly, 99 % of PA showed a TT genotype in LCORL (only 66 % in TB), demonstrating selection for smaller horses. Our results suggest that empirical selection in PA has generated an incipient genomic differentiation in discrete traits which could be used as a marker-assisted selection tool for early selection of polo horses.

Assuntos

RESUMO

Abstract In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.

Resumo Nas últimas décadas, houve avanços significativos no diagnóstico de gliomas difusos, impulsionados pela integração de novas tecnologias. Esses avanços aprofundaram nossa compreensão da oncogênese tumoral, permitindo uma estratificação mais refinada do comportamento biológico dessas neoplasias. Esse progresso culminou na quinta edição da classificação da OMS de tumores do sistema nervoso central (SNC) em 2021. Esta revisão abrangente tem como objetivo elucidar esses avanços de forma multidisciplinar, no contexto da nova classificação. Este artigo irá explorar a patologia morfológica e as técnicas moleculares/genéticas (imuno-histoquímica, sequenciamento genético e perfil de metilação), que são fundamentais no diagnóstico, além da correlação dos radiofenótipos da neuroimagem estrutural com a patologia e a genética. Aborda sucintamente a utilidade da tractografia e da neuroimagem funcional no planejamento cirúrgico. Destacaremos o valor de outras técnicas de imagem funcional, como ressonância magnética de perfusão, espectroscopia e medicina nuclear, na distinção entre a progressão do tumor e as alterações relacionadas ao tratamento. Discutiremos as vantagens das diferentes técnicas de diagnóstico na classificação desses tumores, bem como suas limitações em termos de disponibilidade e utilização. Além disso, os crescentes avanços no processamento de dados, inteligência artificial, radiômica e radiogenômica têm grande potencial e podem em breve exercer uma influência substancial no diagnóstico de gliomas. Essas tecnologias inovadoras têm o potencial de revolucionar nossa abordagem a esses tumores. Em última análise, esta revisão destaca a importância fundamental da colaboração multidisciplinar na utilização dos recentes avanços diagnósticos, com a esperança de traduzi-los em uma melhor qualidade de vida e uma maior sobrevida.

RESUMO

Dystrophinopathies are muscle diseases caused by pathogenic variants in DMD, the largest gene described in humans, representing a spectrum of diseases ranging from asymptomatic creatine phosphokinase elevation to severe Duchenne muscular dystrophy (DMD). Several therapeutic strategies are currently in use or under development, each targeting different pathogenic variants. However, little is known about the genetic profiles of northeast Brazilian patients with dystrophinopathies. We describe the spectrum of pathogenic DMD variants in a single center in northeast Brazil. This is an observational, cross-sectional study carried out through molecular-genetic analysis of male patients diagnosed with dystrophinopathies using Multiplex Ligation-dependent Probe Amplification (MLPA) followed by Next-Generation Sequencing (NGS)-based strategies. A total of 94 male patients were evaluated. Deletions (43.6%) and duplications (10.6%) were the most recurring patterns of pathogenic variants. However, small variants were present in 47.1% of patients, most of them nonsense variants (27.6%). This is the largest South American single-center case series of dystrophinopathies to date. We found a higher frequency of treatment-amenable nonsense single-nucleotide variants than most previous studies. These findings may have implications for diagnostic strategies in less-known populations, as a higher frequency of nonsense variants may mean a higher possibility of treating patients with disease-modifying drugs.

RESUMO

Introduction: This study aimed to investigate the sociodemographic factors, dietary adherence, regular physical activity, and genomic ancestry percentage associated with good glycemic control in Brazilian patients with type 1 diabetes (T1D) using a hierarchical approach. Methods: A cross-sectional study was conducted in 152 T1D patients. Glycated hemoglobin (HbA1C) levels were measured to evaluate the glycemic control status (good, moderate, or poor). Independent factors included sex, age, self-reported skin color, educational level, family income, dietary patterns, and physical activity. The percentage of genomic ancestry (Native American, European, and African) was influenced by a panel of 46 autosomal insertion/deletion ancestry markers. Statistical analyses included receiver operating characteristic curves, and hierarchical logistic regression analysis. Results: The hierarchical analysis, patients who had high dietary adherence showed a positive association with good glycemic control (adjustedOR = 2.56, 95% CI:1.18-5.59, P = 0.016). Thus, age greater than 40 years was associated with good glycemic control compared to the children and adolescents group (adjustedOR = 4.55, 95% CI:1.14-18.1, P = 0.031). Males were associated with good glycemic control (adjustedOR = 2.00, 95% CI:1.01-4.00, P =0.047). Conclusion: The study findings suggest that consistent adherence to dietary regimens is associated with good glycemic control after adjusting for sociodemographic and genomic ancestry factors in an admixed population of T1D patients from Northeast Brazil.

Assuntos

RESUMO

Breast cancer is one of the leading causes of cancer death in women worldwide due to its variable aggressiveness and high propensity to develop distant metastases. The staging can be performed clinically or pathologically, generating the stage stratification by the TNM (T - tumor size; N- lymph node metastasis; M - distant organ metastasis) system. However, cancers with virtually identical TNM characteristics can present highly contrasting behaviors due to the divergence of molecular profiles. This review focuses on the histopathological nuances and molecular understanding of breast cancer through the profiling of gene and protein expression, culminating in improvements promoted by the integration of this information into the traditional staging system. As a culminating point, it will highlight predictive statistical tools for genomic risks and decision algorithms as a possible solution to integrate the various systems because they have the potential to reduce the indications for such tests, serving as a funnel in association with staging and previous classification.

Assuntos

RESUMO

INTRODUCTION: By 2021, the American College of Medical Genetics and Genomics (ACMG) published the last version of their secondary findings (SF) reporting recommendations for cases in which a person receives a genetic test. OBJECTIVE: To determine in a sample of the Colombian population the prevalence of SF for the 59 genes on the ACMG SF v2.0 list associated with 27 genetic diseases. MATERIALS AND METHODS: An analytical cross-sectional study was developed by examining the sequences of 160 exomes. Based on the ACMG guidelines, a variant classification algorithm was designed to filter and select reportable SF. RESULTS: Eleven pathogenic variants were identified in 13/160 (8.13%) patients in genes APOB, BRCA2, CACNA1S, COL3A1, LDLR, MYBPC3, PCSK9, PKP2, PMS2 and RYR2. No association was found between the sociodemographic variables and the SF to report (P > 0,05). CONCLUSION: We reported the first approach of actionable pathogenic variants spectrum in the Colombian population. Given the frequency found in this study and the clinical impact of genomic variants on health, it is essential to actively search for SF having the opportunity to receive genetic counselling, prevention and clinical management.

Assuntos

RESUMO

ABSTRACT: The goals of this study were to evaluate the persistence and the virulence potential of Listeria monocytogenes isolated from beef carcasses obtained in processing facilities in the southern region of Rio Grande do Sul, Brazil, based on pulsed-field gel electrophoresis (PFGE), invasion ability in human colorectal carcinoma cells (HCT-116), internalin A (InlA) expression by Western blot, and identification of mutation points in inlA. PFGE profiles demonstrated that L. monocytogenes isolates were grouped based on their previously identified lineages and serogroups (lineage I: serogroup IIb, n = 2, and serogroup IVb, n = 5; lineage II: serogroup IIc, n = 5). Isolates with indistinguishable genetic profiles through this method were obtained from different slaughterhouses and sampling steps, with as much as a 3-year interval. Seven isolates showed high invasion ability (2.4 to 7.4%; lineage I, n = 6, and lineage II, n = 1) in HCT and expressed InlA. Five isolates showed low cell invasion ability (0.6 to 1.4%; lineage I, n = 1, and lineage II, n = 4) and did not express InlA, and two of them (lineage II, serogroup IIc) presented mutations in inlA that led to premature stop codon type 19 at position 326 (GAA → TAA). The results demonstrated that most L. monocytogenes isolates from lineage I expressed InlA and were the most invasive in HCT, indicating their high virulence potential, whereas most isolates from lineage II showed attenuated invasion because of nonexpression of InlA or the presence of premature stop codon type 19 in inlA. The obtained results demonstrated that L. monocytogenes with indistinguishable PFGE profiles can persist or be reintroduced in beef processing facilities in the studied region and that differences in their virulence potential are based on their lineages and serogroups.

Assuntos

RESUMO

Com a ascensão de animais exóticos no mercado pet, observou-se a necessidade de maiores estudos nesta área. Este estudo teve como objetivo comparar diferentes métodos de sexagem em filhotes de serpentes da espécie Python brongersmai (Bloody Python), sendo utilizados 14 filhotes com aproximadamente 1 ano e 9 meses de vida, oriundos do Criadouro Comercial de Fauna Silvestre e Exótica ­ CCF, autorização de manejo N° 414064, localizado no município de Cornélio Procópio ­ PR. Foi utilizado a introdução da probe metálica de sexagem para contagem de escamas, mensurações do Comprimento Rostro-Cloacal (CRC), Comprimento Pós-Cloacal (CPC), Comprimento Total (CT); avaliação ultrassonográfica dos órgãos reprodutivos e perfil genético (DNA), indicando a fidedignidade de cada um. Observou-se uma eficácia de 100% na determinação do sexo através das amostras de DNA, enquanto a sexagem a partir da contagem de escamas via probe metálica e o dimorfismo sexual por mensurações corporais permitiram apenas uma classificação sexual prévia, sofrendo variações quando comparadas, mostrando-se como métodos inconclusivos. Já a ultrassonografia não foi eficaz para o processo de sexagem em serpentes filhotes de até aproximadamente 1 ano e 9 meses de idade da espécie Python brongersmai.(AU)

With the increment of exotic animal's trade in the pet business, the necessity of more studies in this area was observed. This study aimed at comparing different methods of sex identification in Python brongersmai snakelets (Bloody Python), using 14 baby snakes aged 1 year and 9 months approximately, from commercial breeding of wild and exotic fauna, situated in Cornélio Procópio ­ PR. Methods used were the probing technique introduction, measurement of snout-vent length, post-vent length, total length; ultrasound evaluation of reproductive organs and genetic profile exam (DNA samples), denoting the veracity of each one. A 100% efficacy was observed in the study of sexual determination through DNA samples, while the other methods were shown to be inconclusive, whilst the sexing scale count via the probing technique introduction and sexual dimorphism by bodily measurements permitted only a previous sexual classification, suffering variations when compared, showing to be inconclusive methods. The ultrasound evaluation was not efficient for the sexing process in snakelets aged approximately 1 year and 9 months in Python brongersmai.(AU)

Assuntos

RESUMO

Introducción: La farmacogenómica, como parte de la medicina de precisión, garantiza un tratamiento óptimo de los pacientes basado en su perfil genético. Objetivo: Describir los principales principios en que se sustenta la farmacogenómica y sus aplicaciones a la práctica clínica diaria. Materiales y Métodos: Se realizó una revisión crítica de la farmacogenómica en las bases de datos principales: SciELO, MedLine/PubMed/PMC y Scopus con los descriptores farmacogenómica/pharmacogenomics, farmacogenética/pharmacogenetics, medicina personalizada/personalized medicine y medicina de precisión/precision medicine. También en la biblioteca virtual de salud de Infomed. El periodo de búsqueda y localización de artículos: noviembre 2019-enero 2020. Se seleccionaron artículos publicados entre 2008 y enero de 2020. Resultados: Los principios de la farmacogenómica se basan en el conocimiento del genoma humano que permite determinar el perfil genético de los pacientes y la mejor respuesta al tratamiento medicamentoso con un mínimo de reacciones adversas. Se aplica en diferentes especialidades médicas como oncología, cardiología, medicina interna y endocrinología. Entre los biomarcadores farmacogenéticos estudiados están CACNA1S, RYR1, CYP2D6, SLCO1B1, CYP2C19, F5, CFTR, CYP2C9, CYP4F2, VKORC1, HLA-B, UGT1A1, IFNL3, CYP3A5, TPMT, G6PD, HLA-A, BRCA1, DPYD, RARG, SLC28A3, TPMT y UGT1A6. Conclusiones: Los biomarcadores farmacogenéticos constituyen valiosas herramientas para la identificación de genes implicados en la respuesta medicamentosa, importantes para aplicar una medicina personalizada que mejore la respuesta a los medicamentos y evite o minimice los efectos adversos, aunque quedan desafíos para convertirla en una herramienta de uso frecuente en la práctica médica(AU)

Introduction: Pharmacogenomics, as part of precision medicine, guarantees patients´ optimal treatment based on their genetic profile. Objective: To describe the principles of pharmacogenomics and its application in daily clinical practice. Materials and Methods: A critical review of pharmacogenomics was carried out in SciELO, MedLine/PubMed/PMC, Scopus databases and the Cuban Virtual Health Library using Spanish and English descriptors such as: farmacogenómica/pharmacogenomics, farmacogenética/pharmacogenetics, medicina personalizada/personalized medicine and medicina de precisión/precision medicine. The articles were searched and located during the period between November 2019 and January 2020. The articles published between 2008 and January 2020 were selected. Results: The principles of pharmacogenomics are based on the knowledge of the human genome that allows the determination of the genetic profile of patients and the best response to drug treatment with a minimum of adverse reactions. It is applied in different medical specialties such as Oncology, Cardiology, Internal Medicine and Endocrinology. The most studied pharmacogenetic biomarkers include: CACNA1S, RYR1, CYP2D6, SLCO1B1, CYP2C19, F5, CFTR, CYP2C9, CYP4F2, VKORC1, HLA-B, UGT1A1, IFNL3, CYP3A5, TPMT, G6PD, HLA-A, BRCA1, DPYD, RARG, SLC28A3, TPMT and UGT1A6. Conclusions: Pharmacogenetic biomarkers are valuable tools for the identification of genes involved in the drug response. They are very important in the application of personalized medicine which is intended to improve the response to drugs and avoid or minimize adverse effects. However, substantial challenges remain in respect of making it a frequently used tool in medical practice(AU)

Assuntos

RESUMO

Resumo A farmacogenômica (FGx) investiga a interação entre genes e medicamentos. Através da análise de regiões específicas do DNA, informações sobre o perfil de metabolização do paciente para um determinado fármaco podem ser descritas, assim como o perfil esperado de resposta ao tratamento. Objetivamente, esse tipo de teste pode ter impacto no tratamento de pacientes que não estão respondendo adequadamente a um determinado medicamento, seja pela ausência dos efeitos esperados ou em virtude do aparecimento de efeitos adversos. Neste cenário, o objetivo desta revisão é o de informar o cardiologista clínico sobre esta importante área do conhecimento e atualizá-lo sobre o tema, procurando preencher as lacunas no que diz respeito à relação custo-benefício da aplicação da FGx nas doenças cardiovasculares, além de fornecer informações para a implementação da terapia guiada pela FGx na prática clínica.

Assuntos